#20: Real World Evidence Studies to Evaluate the Safety and Effectiveness of Therapeutic Interventions – Is the Data Fit for Purpose and How Will You Know?
Nancy A. Dreyer, DIAFellow, PhD, MPH, FISPE
- Global Chief, Sci Affairs; Sr VP, Head, Center for Advanced Evidence Generation
- IQVIA, United States
Nancy Dreyer is global chief of scientific affairs at IQVIA Real-World Insights and conducts non-interventional studies and randomized pragmatic trials using primary and/or secondary data. She helped plan the US Nat'l Evaluation System for Health Technology, and advises the Duke Margolis Center and others to advance policy development related to regulatory acceptability of real-world evidence. She is a Fellow of DIA & the Int’l Soc. of Pharmacoepi., and Adjunct Prof of Epidemiology at UNC.
Brian D. Bradbury, PhD, MA
- Executive Director & Head, Data and Analytics, Center for Observational Research
- Amgen, Inc., United States
Brian D. Bradbury is Executive Director and Head of the Data & Analytic Center (DAC) within the Center for Observational Research (CfOR) at Amgen, Inc. He leads a team of epidemiologists, biostatisticians, data scientists and programmers who provide strategic support across the drug development lifecycle. Brian received his DSc in Epidemiology from Boston University and a MA in Education from Pepperdine University. He has authored and co-authored peer-reviewed publications in the areas of pharmacoepidemiology, cancer and kidney disease epidemiology and methods for controlling confounding-by-indication in drug safety studies.